Sangui Biotech International Inc. Announces Earnings Results for the Nine Months Ended March 31, 2016
June 06, 2016 at 08:42 am EDT
Share
Sangui Biotech International Inc. announced earnings results for the nine months ended March 31, 2016. The company achieved revenues from royalty income and product sales of USD 37,005. In the same period of the previous year the comparable revenue amounted to USD 116,500. The operating loss of the quarter decreased compared to the prior year quarter by USD 88,735 to USD 106,795 respectively for the first nine months from USD 579,088 to USD 365,387.
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.
SANGUI BIOTECH INTERNATIONAL, INC. 
